RCS - Moderna Inc - Moderna Reviews Progress at ESG Investor Event

ModernaAnnouncement

07/12/2023 12:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231207:nRSG9522Va&default-theme=true

RNS Number : 9522V  Moderna Inc  07 December 2023

Moderna Reviews its Environmental, Social and Governance (ESG) Progress and
Ambitions at Second ESG Investor Event

The Company's ESG strategy demonstrates its efforts to advance global health
and environmental sustainability, as well as its commitments to employees and
communities

CAMBRIDGE, MA / ACCESSWIRE / December 7, 2023 / Moderna, Inc. (NASDAQ:MRNA)
today will provide an update on its Environmental, Social and Governance (ESG)
strategy at its second ESG Investor Event. Building off its inaugural ESG Day
in November 2022, the Company will highlight the year's progress on its ESG
journey and future work to further impact global health and protect the
environment.

"Our mRNA platform science has benefited patients around the world and with
that comes great responsibility as science alone will not solve the world's
greatest health challenges," said Stéphane Bancel, Chief Executive Officer of
Moderna. "We are committed to moving beyond the power of our technology -
tackling enduring health disparities, engaging with our communities, and
recognizing that human health and planetary health are intricately linked. We
look forward to building on our substantial ESG progress to become the best
version of Moderna."

Moderna's ESG strategy is articulated around five areas:

·      Medicines for Patients: Moderna is leveraging its platform for
many medicines, from vaccines to protect hundreds of millions of people from
common viruses for which no vaccines are available today, to several rare
disease therapies with tremendous opportunity for impact. Within its clinical
trials, Moderna believes a committed approach to offering equal healthcare
accessibility is achievable and necessary. The Company is also committed to
using its platform to help rapidly respond to the greatest public health
threats, pursuing a pipeline of priority programs relevant for outbreak
response and pandemic preparedness. Moderna has long prioritized strategic
collaborations to benefit global health, including its partnership with The
Coalition for Epidemic Preparedness Innovations (CEPI), and Moderna's mRNA
Access program, a collaborative effort that enables researchers around the
world to utilize Moderna's mRNA technology.

·      Environment: Moderna is progressing on its journey toward
net-zero carbon emissions (Scopes 1 & 2) by 2030. The Company has advanced
its overall environmental sustainability program, including through
implementing its sustainability strategy, enhancing its disclosure of key
performance indicators, submitting its first CDP Climate Change questionnaire,
and initiating a climate risk and scenario analysis. These efforts support
internal and external stakeholder expectations for sustainable operations and
Moderna's adaptation to a low-carbon economy.

·      Employees & Culture: Moderna consistently ranks as a top
employer and achieves above benchmark scores on engagement, culture and
belonging. Moderna continues to foster a culture where every employee can
meaningfully contribute to the Company's mission, an effort that serves to
attract and retain the best talent. By living the Company's values and
mindsets every day, the Moderna team is not only advancing mRNA science, but
also building an organization that cares deeply for patients, employees, the
environment, and the community.

·      Community: Moderna is committed to having a positive impact on
communities around the world. Moderna's purpose-driven employees continue to
exemplify the Company's mission, with nearly two out of three employees
participating in volunteering activities or contributing as part of Moderna's
newly instituted employee matching program. The Moderna Charitable Foundation
continues to provide financial support to organizations and causes that
promote public health, advance scientific education, and advocate for
belonging, inclusion, and diversity.

·      Governance & Ethics: Moderna prioritizes accountability and
transparency around its ESG efforts, including through the publication of its
second annual ESG report and continued commitment to disclosing key metrics.
Moderna has initiated an ESG materiality assessment, which includes broad
stakeholder surveys, and is also leveraging AI to build a dynamic analysis of
material topics.

"Delivering on our ESG ambitions is made possible by a strong culture that
embeds the values of transparency, accountability and ownership at all levels
of the organization," said Shannon Thyme Klinger, Moderna's Chief Legal
Officer, Corporate Secretary and President of the Moderna Foundation. "The
same determination that goes into our innovation carries over into our
commitment to positively impact the communities in which we work and live."

Webcast Information

To register for the live webcast of Moderna's ESG Investor Event,
visit https://moderna-esg-day-2023.open-exchange.net/registration
(https://pr.report/Lvcm6TOp) . The archived webcast will be available under
"Events and Presentations" in the Investors section of the Moderna website for
one year following the call: https://investors.modernatx.com
(https://pr.report/3DZREc56) .

About Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the
advancement of mRNA technology, Moderna is reimagining how medicines are made
and transforming how we treat and prevent disease for everyone. By working at
the intersection of science, technology and health for more than a decade, the
company has developed medicines at unprecedented speed and efficiency,
including one of the earliest and most effective COVID-19 vaccines.

Moderna's mRNA platform has enabled the development of therapeutics and
vaccines for infectious diseases, immuno-oncology, rare diseases and
autoimmune diseases. With a unique culture and a global team driven by the
Moderna values and mindsets to responsibly change the future of human health,
Moderna strives to deliver the greatest possible impact to people through mRNA
medicines. For more information about Moderna, please visit modernatx.com and
connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and
LinkedIn.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, as amended, including
statements regarding: Moderna's ability to leverage its mRNA platform for
pandemic preparedness; Moderna's commitment to achieving net-zero carbon
emissions in its global operations for Scopes 1 and 2 by 2030; the potential
of Moderna's mRNA platform for addressing rare diseases and common viruses for
which no vaccines are available today; and Moderna's implementation of its
environmental sustainability program. The forward-looking statements in this
press release are neither promises nor guarantees, and you should not place
undue reliance on these forward-looking statements because they involve known
and unknown risks, uncertainties, and other factors, many of which are beyond
Moderna's control and which could cause actual results to differ materially
from those expressed or implied by these forward-looking statements. These
risks, uncertainties, and other factors include, among others, those risks and
uncertainties described under the heading "Risk Factors" in Moderna's Annual
Report on Form 10-K for the fiscal year ended December 31, 2022, filed with
the U.S. Securities and Exchange Commission (SEC), and in subsequent filings
made by Moderna with the SEC, which are available on the SEC's website
at www.sec.gov (https://pr.report/nA4X3Vht) . Except as required by law,
Moderna disclaims any intention or responsibility for updating or revising any
forward-looking statements contained in this press release in the event of new
information, future developments or otherwise. These forward-looking
statements are based on Moderna's current expectations and speak only as of
the date of this press release

Moderna Contacts

Media:

Chris Ridley

Vice President, Communications

617-800-3651
Chris.Ridley@modernatx.com (mailto:Chris.Ridley@modernatx.com)

Investors:

Lavina Talukdar

Senior Vice President & Head of Investor Relations

617-209-5834
Lavina.Talukdar@modernatx.com (mailto:Lavina.Talukdar@modernatx.com)

SOURCE: Moderna, Inc.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAZZMGZGVMGFZZ